Xagenic
Xagenic Raises $11.8M to Commercialize POC Dx Platform
The company expects the funds to accelerate its efforts to develop and commercialize the Xagenic X1 diagnostic platform.
U of Toronto Study Demos Electrochemical Clamp Chip for Detection of Circulating Nucleic Acids
Premium
The group has licensed the clamp method, as well as earlier technology developments, to Xagenic, which is working to commercialize it in various diagnostic areas.
Xagenic Nabs Exclusive Rights to U of Toronto Mutation Detection Tech
Electrochemical clamp assays, developed at the university could expand Xagenic's X1 platform into the liquid biopsy space.
Xagenic Closes Series B Round Raising $23.8M
NEW YORK (GenomeWeb) – Decentralized molecular diagnostics firm Xagenic today announced the second closing of its Series B financing round, bringing in a total of C$25.5 million (US$23.8 million).
Linda McAllister has joined Toronto-based molecular diagnostics firm Xagenic as chief medical officer.